# BNT324-03 (NCT07365995)

> A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07365995
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: BNT324; Docetaxel; Prednisone/prednisolone
- Enrollment: 736
- Primary outcome: rPFS assessed by BICR
- Primary outcome: OS

## Indexed commentary on BNT324-03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bnt324-03-nct07365995